Journal of Clinical Oncology
Articles in this Issue
Semantic interpretation of prior therapy eligibility in oncology protocols: A comparative analysis of proprietary and open-source large language models (LLMs).
22 Background: Efficient patient accrual in oncology trials is often impeded by the manual burden of interpreting complex...
Perioperative predictors of outcomes in head and neck cancer surgery: A prospective observational analysis.
234 Background: Surgical outcomes in head and neck cancer (HNC) are influenced by patient-related factors (nutritional sta...
Prognostic value of pretreatment systemic immune-inflammation index towards tumor response in patients with locally advanced cervical cancer treated with definitive radiotherapy in Indonesia.
216 Background: The systemic immune-inflammation (SII) is a parameter reflecting immune and inflammatory response. However...
Prognostic significance of undetectable baseline HPV circulating tumor DNA in oropharyngeal cancer.
240 Background: Patients with p16-associated oropharyngeal squamous cell carcinomas (OPSCC) generally experience favorable...
Understanding the impact of the Cancer Drug List on clinicians' prescription patterns in Singapore: A qualitative study.
316 Background: The Cancer Drug List (CDL) introduced by Singapore’s Ministry of Health in September 2022 aligns insurance...
Anthracycline-free platinum-based neoadjuvant chemotherapy in operable triple-negative breast cancer: Interim analysis of pathologic complete response rates and predictors of response.
34 Background: Neoadjuvant chemotherapy (NACT) remains the cornerstone of treatment for operable triple-negative breast ca...
Genetic spectrum of cancer susceptibility: Insights from a 6,093-patient real-world cohort in Singapore.
171 Background: Compared to populations of European-descent, prevalence of pathogenic germline variants in cancer predispo...
Calendar-year seasonality in colorectal and breast cancer screening and first-time uptake: A 6-year single-center time-series to optimize capacity level-loading (2020–2025).
321 Background: Within-year peaks and troughs in screening utilization can create early-year capacity constraints and late...
PET-based radiomics as a preoperative predictor of pathologic lymph node metastasis in lung cancer.
266 Background: Lymph node metastasis (LNM) critically influences treatment strategy in lung cancer, as nodal involvement...
Cost-effectiveness of population screening for Lynch syndrome and hereditary breast and ovarian cancer syndrome in Singapore.
164 Background: Hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome (LS) are the most prevalent heredi...
Real-world efficacy and survival outcomes of novel targeted therapies in advanced hepatocellular carcinoma from low- and middle-income countries.
99 Background: Advanced hepatocellular carcinoma (aHCC) has a dismal prognosis, with a median survival of 8-10 months. Imm...
The HYPCON 3 Trial: A phase II/III randomized study evaluating hypo-fractionated accelerated versus conventional fractionated adjuvant radiation therapy in head and neck malignancies.
TPS244 Background: Postoperative radiotherapy (PORT) for intermediate-risk head and neck squamous cell carcinoma (HNSCC) c...
Predictive scoring systems for molecular response assessment in pediatric chronic-phase chronic myeloid leukemia.
256 Background: For pediatric patients with chronic myeloid leukemia (CML), accurately predicting at the start of imatinib...
Novel triplet combination of orelabrutinib, lenalidomide, and rituximab as frontline therapy for mantle cell lymphoma: Final results of POLARIS multicenter phase II study.
260 Background: Despite the established efficacy of chemoimmunotherapy in untreated mantle cell lymphoma (MCL), its clinic...
A randomized, open-label, phase II trial of short-term combination pharmacotherapy in patients receiving cytotoxic chemotherapy for solid tumors.
305 Background: Patients from resource-limited settings often tolerate standard chemotherapy poorly, resulting in dose red...